Cannabinoids could prevent migraine, study finds
Cannabinoids are just as effective as existing drugs for the prevention of migraine. For cluster headache, however, cannabinoids may only benefit patients who have experienced migraine since childhood.
These are the findings of a new study recently presented at the 3rd Congress of the European Academy of Neurology, held in Amsterdam, the Netherlands.
According to the Migraine Research Foundation, migraine is the third most prevalent illness across the globe, affecting around 1 billion people. In the United States, more than 38 million children and adults experience migraine.
Some people simply consider migraine as a “bad headache,” but it can be much more serious.
Migraine attacks normally involve a severe, recurrent throbbing pain on one or both sides of the head, which can last anywhere between 4 and 72 hours.
These attacks may be accompanied by other disabling symptoms, including dizziness, nausea, vomiting, light sensitivity, and tingling or numbness of the face or extremities.
Cluster headache is defined as the onset of brief but very painful headaches that can strike several times per day. Pain normally occurs on one side of the head, usually in or around one eye.
Cluster headache is much rarer than migraine; the World Health Organization (WHO) estimate that cluster headaches affect fewer than 1 in 1,000 adults worldwide.
Acute pain reduced by 55 percent
For the new research, study leader Dr. Maria Nicolodi, of the Interuniversity Center in Italy, and colleagues set out to investigate this association further, by assessing the efficacy of cannabinoids in the treatment of migraine and cluster headache.
The first phase of the study included 48 adults with chronic migraine. Participants were given varying doses of a combination of two compounds.
One compound consisted of 19 percent tetrahydrocannabinol (THC), the primary psychoactive component of marijuana, while the other compound contained 9 percent cannabidiol (CBD), another active marijuana compound.